P. S. Nelson

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer

This study identifies ONECUT2 as a master transcription factor that drives resistance in prostate cancer through multiple mechanisms, including activation of neuroendocrine and adenocarcinoma variants, and shows that its inhibition can suppress treatment-resistant lineage plasticity.

Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts

The paper characterizes the proteome and phosphoproteome of prostate cancer patient-derived xenografts to identify differences between neuroendocrine-like and adenocarcinoma subtypes.

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator

This study uses a CRISPR screen to identify genes critical for macrophage-mediated killing of prostate cancer cells, revealing AR as an immunomodulator that promotes resistance to macrophage attack.

Analysis of evolutionary dynamics and clonal architecture in prostate cancer

This study analyzes prostate cancer clonal architecture and evolutionary dynamics in 845 tumors, finding that Black patients have more monoclonal tumors but higher recurrence rates, and identifies new mutational signatures linked to subclones.

Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes

This paper identifies nucleosome patterns in ctDNA that distinguish advanced prostate cancer phenotypes, achieving high accuracy in classification using a prediction model.

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy

This study develops STEAP1 CAR T cell therapy for advanced prostate cancer, showing potent antitumor activity and safety in preclinical models, but also identifies antigen loss as a resistance mechanism.

Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer

This study identifies biomarkers beyond B7H3 expression that predict response to a B7H3-ADC in metastatic prostate cancer models, improving therapeutic efficacy.

Defining cellular population dynamics at single cell resolution during prostate cancer progression

This study examines prostate cancer progression at single-cell resolution, identifying castration-resistant luminal cells and their role in treatment resistance and tumor heterogeneity.

Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling

The paper identifies stem-like luminal cells with elevated JAK/STAT signaling as a source of multilineage plasticity in prostate cancer, offering a therapeutic target.

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

Targeting RET Kinase in Neuroendocrine Prostate Cancer

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.

EZH2 co-opts gain-of-function p53 mutants to promote cancer growth and metastasis

This study identifies EZH2 as a p53 mRNA-binding protein that enhances translation of gain-of-function p53 mutants, promoting cancer growth and metastasis, and shows that inhibiting EZH2 causes synthetic lethality in these cells.